MDGL vs. ALKS, FOLD, GERN, IONS, RCKT, DVAX, LGND, IRWD, MNKD, and YMAB
Should you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Alkermes (ALKS), Amicus Therapeutics (FOLD), Geron (GERN), Ionis Pharmaceuticals (IONS), Rocket Pharmaceuticals (RCKT), Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), Ironwood Pharmaceuticals (IRWD), MannKind (MNKD), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical preparations" industry.
Madrigal Pharmaceuticals (NASDAQ:MDGL) and Alkermes (NASDAQ:ALKS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.
Alkermes has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
Madrigal Pharmaceuticals has a beta of -0.33, suggesting that its share price is 133% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.
98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 23.9% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Madrigal Pharmaceuticals presently has a consensus target price of $356.73, indicating a potential upside of 63.67%. Alkermes has a consensus target price of $35.38, indicating a potential upside of 43.86%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Alkermes.
In the previous week, Alkermes had 10 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 23 mentions for Alkermes and 13 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.37 beat Alkermes' score of 0.24 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.
Alkermes has a net margin of 25.17% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Alkermes' return on equity of 20.31% beat Madrigal Pharmaceuticals' return on equity.
Alkermes received 238 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 70.69% of users gave Alkermes an outperform vote while only 68.56% of users gave Madrigal Pharmaceuticals an outperform vote.
Summary
Alkermes beats Madrigal Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Madrigal Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Madrigal Pharmaceuticals Competitors List
Related Companies and Tools
